Friday, 20 September 2019

Japan News

  • TSRI, Takeda expand research collaboration

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 14 Mar, 2013

    Singapore: The Scripps Research Institute (TSRI) and Takeda Pharmaceutical plan to expand their recent research collaboration to search for new drug targets for a variety of diseases. The...Read more

  • Japanese I'rom acquires 18% in Australian IDT

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 07 May, 2013

    Singapore: Japanese company I'rom Holdings will acquire an 18.8 percent stake in IDT Australia. I'rom is listed on the Tokyo Stock Exchange and is one of the leading providers of site manag...Read more

  • Iressa deaths: Japanese High Court rules in favor of AZ

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 28 May, 2012

    Singapore: The Japanese unit of AstraZeneca (AZ), has been acquitted, in a case that had held the firm responsible for the deaths of several individuals due to the side effects of the firm'...Read more

  • Asia vaccine strategists call for collaboration

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 18 Jun, 2013

    Asia needs a solution, that goes beyond traditional structure, models and pathways, to meet the essential vaccine supply for public health, and stronger partnership between international pl...Read more

  • Daiichi Sankyo, Ranbaxy to leverage synergies in Thailand

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 24 Apr, 2013

    Singapore: Japan's Daiichi Sankyo and Ranbaxy Laboratories have plans to integrate their business operations in Thailand, to leverage and maximize the synergies of the Hybrid Business Model...Read more

  • RIKEN's new chip detects traces of miRNA in only 20 mins

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 09 Nov, 2012

    Singapore: A new power-free microfluidic chip developed by researchers at the RIKEN Advanced Science Institute, Japan, has enabled the detection of microRNA from extremely small sample vol...Read more

  • Hoya appoints new executive officer

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 26 May, 2014

    Singapore: Japan based Hoya Corporation has appointed Mr Augustine Yee as its executive officer, chief legal officer and head of corporate development and affairs. As the company's first c...Read more

  • Takeda's center among Chicago's top 100 workplaces

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 14 Nov, 2012

    Singapore: Takeda Pharmaceuticals' Deerfield campus has been listed among Chicago's top 100 workplaces by the Chicago Tribune. The list of the best places to work in the Chicago area is ba...Read more

  • Eisai launches beauty drink in Japan

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 26 Feb, 2013

    Singapore: Japan-based Eisai is going to launch its new carbonated supplement drink named 'Chocola BB Sparkling + Fiber'. The drink will contain Niacin and would be available at convenience...Read more

  • Eisai seeks nod for Helicobacter Pylori treatment

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 01 Jun, 2012

    Singapore: Eisai, which has its headquarters in Tokyo, has submitted a marketing authorization application to Japan's Ministry of Health, Labor and Welfare for approval of two types of new ...Read more

  • Will Keryx's ferric citrate NDA get nod in Japan?

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 08 Jan, 2013

    Singapore: Keryx Biopharmaceuticals announced that its Japanese partner, Japan Tobacco (JT), has filed a New Drug Application (NDA) with the Japanese Ministry of Health, Labour and Welfare...Read more

  • FDA accepts sNDA for Astellas cancer drug

    Japan |  Regulatory | By BioSpectrum Bureau  | 0 Comment | 17 Jan, 2013

    Singapore: The US FDA has accepted Astellas Pharma's US subsidiary filing of a supplemental New Drug Application (sNDA) for Tarceva (erlotinib) for first-line use in people with locally adv...Read more

  • EMA to review marketing plea for antipsychotic medication

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 29 Oct, 2012

    Singapore: The European Medicines Agency (EMA) has accepted the marketing authorization application for review of an atypical antipsychotic medication lurasidone hydrochloride. The product ...Read more

  • Ranbaxy advisory: All our products are safe and efficacious

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 03 Jun, 2013

    New Delhi: Ranbaxy issued an advisory claiming that all their products in the Indian and global markets are safe and efficacious. The firm revealed that the advisory was issued in public i...Read more

  • Amgen to acquire Onyx for $10 bn cash

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 26 Aug, 2013

    Singapore: Global biopharmaceutical company Amgen plans to acquire all the outstanding shares of Onyx Pharmaceuticals for $125-per-share, totalling to $10.40 billion, in cash. The deal woul...Read more

  • Effient trial by Daiichi, Lilly fails to meet primary endpoint

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 27 Aug, 2012

    Singapore: The TRILOGY ACS study, a phase III trial comparing prasugrel plus aspirin to clopidogrel plus aspirin in patients with unstable angina (UA) or non-ST elevation myocardial infarct...Read more

  • Takeda ends 3-year-old-deal with Amylin

    Japan |  News | By BioSpectrum Bureau  | 0 Comment | 26 Dec, 2012

    Singapore: Takeda Pharmaceutical mutually terminated its worldwide agreement with Amylin Pharmaceuticals, which was originally signed in October 2009, to co-develop and commercialize compo...Read more

  • EMA committee positive on Teduglutide

    Japan |  Regulatory | By BioSpectrum Bureau  | 0 Comment | 25 Jun, 2012

    Singapore: The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion for the medicinal product teduglutide (tradename in Euro...Read more



Podcast

 

Survey Box

Is Pharma innovation getting inhibited in APAC?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls